Short report: Evaluation of the potency and stability of a candidate vaccine against American cutaneous leishmaniasis

American Journal of Tropical Medicine and Hygiene

Volumn 61, Issue 2, 1999, Pages 294-295

  Mayrink, Wilson ^a   Pinto, Jorge ^a   Da Costa, Carlos ^b   Toledo, Vicente ^a   Guimarães, Tânia ^a   Genaro, Odair ^a   Vilela, Luciano ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b BioBràs S A   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; LEISHMANIA VACCINE; THIOMERSAL;

ADULT; ARTICLE; AUTOCLAVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; FEMALE; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; LEISHMANIA; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SKIN LEISHMANIASIS; VACCINE PRODUCTION;

LEISHMANIA AMAZONENSIS; LEISHMANIA MAJOR; PROTOZOA;

EID: 0032777120     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1999.61.294     Document Type: Article

References (13)

1. Desjeux P, 1996. Leishmaniaisis: public health aspects and control. Clin Dermatol 14: 417-423.
2. Lainson R, Shaw JJ, 1978. Epidemiology and ecology of leishmaniasis in Latin America. Nature 273: 595-600.
3. Modabber F, 1995. Vaccines against leishmaniasis. Ann Trop Med Parasitol 89: 83-88.
4. Mayrink W, da Costa CA, Magalhães PA, Melo MN, Oliveira-Lima A, Michalick MSM, Williams P, 1979. A field trial of a vaccine against American dermal leishmaniasis. Trans R Soc Trop Med Hyg 73: 385-387.
5. Antunes CMF, Mayrink W, Magalhães PA, da Costa CA, Melo MN, Dias M, Michalick MSM, Williams P, Oliveira-Lima A, Vieira JBF, 1986. Controlled field trial of a vaccine against New World cutaneous leishmaniasis. Int J Epidemiol 15: 572-580.
6. Mayrink W, Williams P, da Costa CA, Magalhães PA, Melo MN, Dias M, Oliveira-Lima A, Michalick MSM, Carvalho EF, Barros GC, Sessa PA, Alencar JTA, 1985. An experimental vaccine against American dermal leishmaniasis: experience in the state of Espirito Santo, Brazil. Ann Trop Med Parasitol 79: 259-269.
7. Mendonça SCF, DeLuca PM, Mayrink W, Restom TG, Conceição-Silva F, da-Cruz AM, Bertho AL, da Costa CA, Genaro O, Toledo VPCP, Coutinho SG, 1995. Characterization of the human T lymphocyte-mediated immune response induced by a vaccine against American tegumentary leishmaniasis. Am J Trop Med Hyg 53: 195-201.
8. da Costa CA, Afonso LCC, Toledo VPCP, Mayrink W, 1992. Immune responses and protection induced in mice by an industrialized vaccine against American cutaneous leishmaniasis. Parassitologia 34: 45-51.
9. Carvalho EM, Barral A, Pedral-Sampaio D, Barral-Netto M, Badaró R, Rocha H, Johnson WD, 1992. Immunological cell markers of clinical evolution in children recently infected by L. chagasi. J Infect Dis 165: 535-540.
10. da Costa CA, Toledo VPCP, Genaro O, Williams P, Mayrink W, 1996. Montenegro skin test evaluation of the composition and stability of the antigen preparation. Mem Inst Oswaldo Cruz 91: 193-194.
11. Costa TC, Toledo VPCP, da Costa CA, Genaro O, Mayrink W, 1997. Assessment of the stability of a cutaneous leishmaniasis vaccine using immunological parameters. Mem Inst Oswaldo Cruz 92 (suppl 1): 286-287.
12. Sharifi I, Fekri AR, Aflatonian MR, Khamesipour A, Nadim A, Mousavi MRA, Dowlati Y, Godal T, Zicker F, Smith PG, Modabber F, 1998. Randomized vaccine trial of a single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351: 1540-1543.
13. Armijos RX, Weigel MM, Aviles H, Maldonado R, Racines J, 1998. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity and efficacy during the first 12 months of follow-up. J Infect Dis 177: 1352-1357.